In summary, targeting Tim-3 with anti-Tim3 agents (anti-Tim-3 antibodies and Tim-3Apt) and in combination with other immune checkpoint inhibitors, CD137 agonists, and chemotherapy agents and combination with radiotherapy shows excellent anti-tumor effects in preclinical studies. This evidence concerns the gene HAVCR2 and neoplasm.